Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

204
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
204
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

693
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
693
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

538
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
538
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

895
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
895
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

741
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
741
Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

1.3K
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
1.3K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Prognostic factors related to all-cause mortality in very long-term follow-up of patients with heart failure: the REMADHE trial extended analysis.

BMC cardiovascular disorders·2026
Same author

iCARDIO Alliance Global Implementation Guidelines on Heart Failure 2025.

Heart views : the official journal of the Gulf Heart Association·2026
Same author

Cardiotoxicity of monoclonal antibody-based therapies in breast cancer: a contemporary narrative review.

Cardio-oncology (London, England)·2026
Same author

Discovery and Optimization of Thienopyrazine RNA-Splicing Modulators for the Treatment of Huntington's Disease.

Journal of medicinal chemistry·2026
Same author

Carvedilol for Prevention of Chemotherapy-Induced Cardiotoxicity: Final Results of the CECCY Trial.

JACC. CardioOncology·2026
Same author

Reverse Remodelling, Myocardial Recovery and Remission in Heart Failure with Reduced Ejection Fraction: Clinical Implications and Management Strategies.

Cardiac failure review·2026

相关实验视频

Updated: Jan 9, 2026

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility
04:22

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility

Published on: May 30, 2025

775

席尔德纳菲尔对运动,神经激素激活和充血性心力衰竭的勃起功能障碍的影响:双盲,安慰剂控制,随机研究,随后进行勃起功能障碍的前性治疗.

Edimar Alcides Bocchi1, Guilherme Guimarães, Amilcar Mocelin

  • 1Heart Failure Clinics, Heart Institute, São Paulo University Medical School, São Paulo, Brazil. dcledimar@incor.usp.br

Circulation
|August 28, 2002
PubMed
概括
此摘要是机器生成的。

西尔德纳菲尔有效治疗患有充血性心力衰竭 (CHF) 的男性勃起功能障碍 (ED),改善运动能力和生活质量. 这种药物耐受性很好,可以减少身体活动期间的心脏工作负担.

更多相关视频

Effects of Surgical Masks on Cardiopulmonary Function in Healthy Subjects
06:57

Effects of Surgical Masks on Cardiopulmonary Function in Healthy Subjects

Published on: February 12, 2021

3.6K
Surgical Placement of Catheters for Long-term Cardiovascular Exercise Testing in Swine
12:37

Surgical Placement of Catheters for Long-term Cardiovascular Exercise Testing in Swine

Published on: February 9, 2016

13.8K

相关实验视频

Last Updated: Jan 9, 2026

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility
04:22

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility

Published on: May 30, 2025

775
Effects of Surgical Masks on Cardiopulmonary Function in Healthy Subjects
06:57

Effects of Surgical Masks on Cardiopulmonary Function in Healthy Subjects

Published on: February 12, 2021

3.6K
Surgical Placement of Catheters for Long-term Cardiovascular Exercise Testing in Swine
12:37

Surgical Placement of Catheters for Long-term Cardiovascular Exercise Testing in Swine

Published on: February 9, 2016

13.8K

科学领域:

  • 心脏病学 心脏病学
  • 泌尿器科 泌尿器科 泌尿器科 泌尿器科
  • 药理学 药理学是指药理学的学科.

背景情况:

  • 勃起功能障碍 (ED) 是诊断为充血性心力衰竭 (CHF) 的患者中普遍存在的疾病.
  • 勃起障碍显著降低了患者的生活质量,并可能对治疗坚持产生负面影响,可能阻碍心血管疾病管理的有效性.

研究的目的:

  • 为了研究西尔德纳菲尔在治疗男性心脏不全症时的疗效和安全性.
  • 评估西尔代纳菲尔对该患者群体的运动能力和心血管参数的影响.

主要方法:

  • 一项随机,双盲,安慰剂控制,双向交叉研究,涉及23名患有心血管衰竭的男性.
  • 参与者接受了心肺运动测试 (6分钟的步行测试和最大运动测试),有和没有西尔代纳菲尔.
  • 使用国际勃起功能指数 (IIEF) 和运动性能指标来评估有效性.

主要成果:

  • 西尔德纳菲尔在运动前和运动期间显著降低了心率和血压.
  • 药物减轻了运动期间心率的增加,并改善了峰值氧气消耗 (VO2) 和运动持续时间.
  • 在国际勃起功能指数得分中观察到显著改善,表明ED治疗有效.

结论:

  • 西尔德纳菲尔是一种耐受性良好的,有效的治疗男性心脏衰竭的ED.
  • 这种药物增强了运动能力,并可能减少肌肉心脏在运动期间的氧气需求.
  • 这些发现表明,西尔德纳菲尔可以改善性功能和身体表现在CHF患者.